Vous avez cherché: bortezomib (Danois - Anglais)

bortezomib
- keep this leaflet.

bortezomib sun seponeres
discontinue bortezomib sun

aktivt stof: bortezomib.
the active substance is bortezomib.

• aktivt stof: bortezomib.
each vial contains 1 mg or 3.5 mg of bortezomib (as a

bortezomib accord seponeres
discontinue bortezomib accord

se produktresumeet for bortezomib.
see the spc for bortezomib.

bz = bortezomib; dex = dexamethason
bz= bortezomib; dex=dexamethasone

8 behandlingscyklusser med bortezomib sun.
8 cycles of bortezomib sun therapy.

bortezomib-kombinationsbehandling med dexamethason
bortezomib combination treatment with dexamethasone

andre oplysninger om bortezomib sun
other information about bortezomib sun

bortezomib er et cytotoksisk middel.
bortezomib is a cytotoxic agent.

hvordan anvendes bortezomib accord?
how is bortezomib accord used?

bortezomib sun-behandling skal tilbageholdes.
bortezomib sun therapy should be withheld

afbryd behandling med bortezomib hospira
bortezomib hospira therapy should be withheld

det indeholder det aktive stof bortezomib.
it contains the active substance bortezomib.

bortezomib accord-behandling skal tilbageholdes
bortezomib accord therapy should be withheld

bemærk: bortezomib sun er en cellegift.
note: bortezomib sun is a cytotoxic agent.

bortezomib accord må ikke administreres intratekalt.
bortezomib accord should not be administered intrathecally.

bortezomib- pk efter behandling med enkeltdosis
description as an adjunct to the population pharmacokinetics (pk) study nested in the ongoing phase iii trial, the applicant will conduct a clinical pk study in 24 patients with multiple myeloma receiving bortezomib at the doses of 1.0 and 1.3 mg/ m2, twice a week for two weeks followed by a rest period.

virkningsmekanisme bortezomib er en proteasom- hæmmer.
mechanism of action bortezomib is a proteasome inhibitor.